Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tanshinone I is a natural abietane diterpenoid quinone compound isolated from the roots of Salvia miltiorrhiza (Danshen), a traditional Chinese medicinal herb. It is classified as a small molecule and has demonstrated a wide range of biological activities, including anti-cancer, anti-inflammatory, and anticoronaviral effects. Mechanistically, tanshinone I has been shown to suppress growth and invasion of human cancer cells by regulating adhesion molecules such as ICAM‑1 and VCAM‑1. It also exhibits inhibitory effects on angiogenesis and cell proliferation in various preclinical models. While it is widely used in experimental research, its clinical development status remains largely investigational[1][2][3][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on tanshinone I.